Build status - In Progress

A study to assess the safety and tolerability of nebulized PC945 for prophylaxis or pre-emptive therapy against pulmonary aspergillosis in lung transplant recipients.

A study to assess the safety and tolerability of nebulized PC945 for prophylaxis or pre-emptive therapy against pulmonary aspergillosis in lung transplant recipients.
Recruiting
18 years - 99 years
All
Phase 2
100 participants needed
1 Location

Brief description of study

The purpose of this study is to learn about how safe and effective a new investigational drug, PC945, can be. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). PC945 is an inhaled drug being studied for the prevention of a common fungus found in the air, Aspergillus, from causing disease in the lungs or airways.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: pulmonary aspergillosis,lung transplant
  • Age: 18 years - 99 years
  • Gender: All

Male and Female, Age 18 or older, received either a single or double lung transplant

Updated on 04 Aug 2024. Study ID: 850194

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center